• Francisco J Morera Ocón Hospital Clínico Universitario de Valencia
  • Bruno Camps Vilata Hospital Clínico Universitario de Valencia


Introduction: The role of systemic chemotherapy (SC) in the management of metastatic appendiceal adenocarcinomas is not defined.

Methods: We perform an observational study of patients treated of peritoneal metastases from appendiceal neoplasm between June 2004 and December 2017. They were referred to our hospital for CRS HIPEC. Systemic Chemotherapy regimens were decided by the referring oncologist. We analyze PCI, CC, and use of SC. Overall survival and progression free survival were compared attending to histologic subtype (high- and low-grade adenocarcinomas) and the use of SC.

Results: 60 patients were included, 26 were male, median age 63 years (26-81). Median follow-up of 38 months [2-155]. The predominant histologic subtype was mucinous adenocarcinoma (58/60), 1 was colonic type, and 1 adenocarcinoid with signet ring cells. Four patients had extraperitoneal metastases, 2 hepatic metastases (1 with high-grade mucinous adenocarcinoma and 1 with colonic adenocarcinoma), and 2 in the low-grade group developed parenchymal lung disease. Three patients died in the postoperative period. Systemic chemotherapy was administered in 26 patients/57. No difference were observed in the OS and PFS regardless the use of SC in the high- and in the lo-grade groups.

Conclusions: The use of SC in low-grade mucinous adenocarcinoma subtype is not supported by our results, and there is no literature date supporting it neither. Palliative SC in high-grade patients deserves of clinical trials for been accepted as standard of care, when benefits are not clearly established by evidence and toxicities are not negligible.


Author Biographies

Francisco J Morera Ocón, Hospital Clínico Universitario de Valencia

Hospital Clínico universitario de Valencia

Servicio de Cirugía

Médico Adjunto

Bruno Camps Vilata, Hospital Clínico Universitario de Valencia

Hospital Clínico universitario de Valencia

Servicio de Cirugía

Jefe de Sección


1. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449-2456

2. Tejani MA, ter Veer A, Milne D, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc 2014;12: 1123-30

3. Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management. Oncologist 2017; 22:1107-16

4. Saphiro JF, Chase JL, Wolff RA, et al. Modern s. 316-22 Systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer 2010; 116

5. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-74

6. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In : Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of tumors of the digestive system. Lyon, IARC; 2010: 122-125.

7. Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. British J Cancer 2008; 99: 591-596.

8. Carr NJ, Cecil TH, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia. Am J Surg PAthol 2016; 40: 14-16

9. McCuster ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology, and End Results program. Cancer 2002; 94: 1973-1998

10. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012; 19:1379-85

11. Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2014; 109: 740-5.

12. Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer 2016; 122: 213-21

13. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012;23: 652-658

14. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010; 102: 576-81

15. Sahib WL, Martin LK, Choi M, et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. The Oncologist 2015; 20:907-914

16. Kitai T. Pulmonary metastasis from pseudomyxoma peritonei. Gastroenterol Res Pract 2012; doi: 10.1155/2012/690256

17. Xu L, Burke A. Pulmonary metastasis from a low grade mucinous appendiceal neoplasm. Pathology 2013; 45: 185-88